|
SurModics Inc licenses nanotechnology
drug delivery system from PharmaSol GmbH
Other Topics:
MEMS and
Nanomaterial Consumer Guide
SurModics Inc
July 15, 2008
SurModics Inc (Nasdaq:SRDX),
a provider of surface modification and drug delivery
technologies to the healthcare industry, reported on 14 July
that the company's subsidiary, Brookwood Pharmaceuticals has
acquired the license to lipid nanoparticle technology from
PharmaSol GmbH of Berlin, Germany.
The agreement provides Brookwood with the exclusive rights
to all pharmaceutical applications of the nanoparticle
technology. |
|
The PharmaSol
technology can be used to formulate drugs into
nanostructured lipid carriers (NLCs), which offer a number
of advantages over other drug delivery nanotechnologies such
as liposomes, emulsions and solid lipid nanoparticles.
Reportedly, nanotechnology, sometimes referred to as the
science of the extremely small, has across-the-board
economic and quality-of-life implications. Nanoscale
materials are currently used in electronic, cosmetic,
automotive and medical products. |
